4-异丙基环己烷甲腈 | 191092-95-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 4-异丙基环己烷甲腈
• 中文别名: (R)-(+)-1-苯甲基吡咯烷-2-甲醇
• 英文名称: 4-isopropylcyclohexanecarbonitrile
• 英文别名: 4-(Propan-2-yl)cyclohexane-1-carbonitrile；4-propan-2-ylcyclohexane-1-carbonitrile
• CAS: 191092-95-2
• 化学式: C₁₀H₁₇N
• 分子量: 151.252
• InChiKey: FDDPLWVKAZGUBJ-UHFFFAOYSA-N

物化性质

• 沸点：
  239.9±9.0 °C(Predicted)
• 密度：
  0.88±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-溴苯腈 、 4-异丙基环己烷甲腈 在 (2,2,6,6-tetramethylhexahydropyridin-1-yl)zinc (II) lithium chloride 、 2-双环己基膦-2',6'-二甲氧基联苯 、 CCl₂CuLi₂N 、 palladium diacetate 作用下， 以 四氢呋喃 为溶剂， 反应 0.33h， 生成 4-((1SR,4SR)-1-cyano-4-isopropylcyclohexyl)benzonitrile 、 4-((1SR,4SR)-1-cyano-4-isopropylcyclohexyl)benzonitrile
  参考文献：
  名称：

  Cyclohexylcarbonitriles: Diastereoselective Arylations with TMPZnCl·LiCl

  摘要：

  Deprotonating substituted cyclohexanecarbonitriles with TMPZnCl center dot LiCl affords zincated nitriles that diastereoselectively couple with aryl bromides in the presence of catalytic Pd(OAc)(2), and S-Phos. Steric and electronic effects influence the diastereoselectivity; 4-t-butyl-, 4-TBSO-, and 2-Me-cyclohexanecarbonitriles exert virtually complete diastereocontrol whereas modest diastereoselectivity is observed with 4-i-Pr-, 4-Me-, and 3-Me-cyclohexanecarbonitriles. The unusual diastereoselectivity trends should prove useful for synthesizing substituted cyclohexanecarbonitrile-containing pharmaceuticals.

  DOI：

  10.1021/jo301127n
• 作为产物：
  描述：

  4-异丙基环己酮 、 对甲基苯磺酰甲基异腈 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 4.33h， 以80%的产率得到4-异丙基环己烷甲腈
  参考文献：
  名称：

  Cyclohexylcarbonitriles: Diastereoselective Arylations with TMPZnCl·LiCl

  摘要：

  Deprotonating substituted cyclohexanecarbonitriles with TMPZnCl center dot LiCl affords zincated nitriles that diastereoselectively couple with aryl bromides in the presence of catalytic Pd(OAc)(2), and S-Phos. Steric and electronic effects influence the diastereoselectivity; 4-t-butyl-, 4-TBSO-, and 2-Me-cyclohexanecarbonitriles exert virtually complete diastereocontrol whereas modest diastereoselectivity is observed with 4-i-Pr-, 4-Me-, and 3-Me-cyclohexanecarbonitriles. The unusual diastereoselectivity trends should prove useful for synthesizing substituted cyclohexanecarbonitrile-containing pharmaceuticals.

  DOI：

  10.1021/jo301127n

文献信息

• [EN] DESACETOXYTUBULYSIN H AND ANALOGS THEREOF<br/>[FR] DÉSACÉTOXYTUBULYSINE H ET SES ANALOGUES
  申请人：UNIV RICE WILLIAM M

  公开号：WO2016138288A1

  公开（公告）日：2016-09-01

  In one aspect, the present disclosure provides tubulysin analogs of the formula (I) wherein R1, R2, R3, R4, X1, X2, X3, and A1 are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein.

  在一个方面，本公开提供了公式（I）的tubulysin类似物，其中R1、R2、R3、R4、X1、X2、X3和A1如本文所定义。在另一个方面，本公开还提供了制备本公开化合物的方法。在另一个方面，本公开还提供了药物组合物和使用本公开化合物的方法。
• AMINATION AND HYDROXYLATION OF ARYLMETAL COMPOUNDS
  申请人：WILLIAM MARSH RICE UNIVERSITY

  公开号：US20180057444A1

  公开（公告）日：2018-03-01

  In one aspect, the present disclosure provides methods of preparing a primary or secondary amine and hydroxylated aromatic compounds. In some embodiments, the aromatic compound may be unsubstituted, substituted, or contain one or more heteroatoms within the rings of the aromatic compound. The methods described herein may be carried out without the need for transition metal catalysts or harsh reaction conditions.

  在一个方面，本公开提供了制备初级或次级胺和含羟基芳香化合物的方法。在一些实施例中，芳香化合物可以是未取代的、取代的，或者在芳香化合物的环中含有一个或多个杂原子。本文描述的方法可以在不需要过渡金属催化剂或苛刻反应条件的情况下进行。
• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR TRAITER DES ÉTATS ASSOCIÉS À UNE ACTIVITÉ DE STING
  申请人：IFM DUE INC

  公开号：WO2021138434A1

  公开（公告）日：2021-07-08

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

  本公开涉及化学实体（例如，一种化合物或药用可接受盐，和/或水合物，和/或共晶体，和/或该化合物的药物组合），可抑制（例如，拮抗）干扰素基因激活器（STING）。所述化学实体可用于治疗条件、疾病或障碍，其中增加（例如，过度）STING激活（例如，STING信号传导）对主体（例如，人类）的病理和/或症状和/或病情进展有贡献（例如，癌症）。本公开还涉及含有相同化学实体的组合物，以及使用和制备这些组合物的方法。
• [EN] TRANSITION METAL FREE METHODS OF SYNTHESIS OF BIARYL COMPOUNDS<br/>[FR] PROCÉDÉS DE SYNTHÈSE, SANS MÉTAL DE TRANSITION, DE COMPOSÉS BIARYLE
  申请人：UNIV RICE WILLIAM M

  公开号：WO2017083719A1

  公开（公告）日：2017-05-18

  The present disclosure provides methods of preparing biaryl compounds which do not require transition metal catalysts. In yet another aspect, the present disclosure provides pharmaceutical compositions comprising compounds as described herein and pharmaceutically acceptable carriers.

  本公开提供了制备联苯化合物的方法，这些方法不需要过渡金属催化剂。另一方面，本公开提供了包括所述化合物和药用可接受载体的制药组合物。
• [EN] EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES THEREOF<br/>[FR] ANALOGUES D'ÉPOTHILONE, PROCÉDÉS DE SYNTHÈSE, PROCÉDÉS DE TRAITEMENT, ET CONJUGUÉS MÉDICAMENTEUX DE CEUX-CI
  申请人：UNIV RICE WILLIAM M

  公开号：WO2017066606A1

  公开（公告）日：2017-04-20

  In one aspect, the present disclosure provides epothilone analogs of the formula (I) wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein. Additionally, drug conjugates with cell targeting moieties of the compounds are also provided.

  在一个方面，本公开提供了公式（I）中变量如本文所定义的紫杉醇类似物。在另一个方面，本公开还提供了制备本文披露的化合物的方法。在另一个方面，本公开还提供了药物组合物和使用本文披露的化合物的方法。此外，还提供了具有细胞靶向基团的药物共轭物。